Cadrenal Therapeutics (CVKD)
4.44
+0.13 (3.02%)
Upcoming Events
Latest Headlines
Form 4 Cadrenal Therapeutics, For: Jun 03 Filed by: Pham Quang X
June 5, 2026 5:27 PM - SEC Filing
Form 8-K Cadrenal Therapeutics, For: May 28
June 3, 2026 4:26 PM - SEC Filing
Cadrenal Therapeutics to present drug candidates at BIO 2026 event
June 3, 2026 9:02 AM - StreetInsider
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
June 3, 2026 9:00 AM - Globe NewsWire
Form 4 Cadrenal Therapeutics, For: May 29 Filed by: Pham Quang X
June 2, 2026 8:34 PM - SEC Filing
Form 4 Cadrenal Therapeutics, For: May 11 Filed by: Pham Quang X
May 29, 2026 4:32 PM - SEC Filing
Form 4 Cadrenal Therapeutics, For: May 22 Filed by: Pham Quang X
May 26, 2026 9:07 PM - SEC Filing
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
May 19, 2026 4:30 PM - Globe NewsWire
Form 144 Cadrenal Therapeutics, Filed by: Pham Quang X
May 11, 2026 4:38 PM - SEC Filing
Form 8-K Cadrenal Therapeutics, For: May 07
May 7, 2026 8:36 AM - SEC Filing
Form 10-Q Cadrenal Therapeutics, For: Mar 31
May 7, 2026 8:31 AM - SEC Filing
Cadrenal Therapeutics, Inc. (CVKD) Tops Q1 EPS by 31c
May 7, 2026 8:31 AM - StreetInsider
Cadrenal Therapeutics receives FDA guidance for CAD-1005 phase 3 trial
May 7, 2026 8:30 AM - StreetInsider
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
May 7, 2026 8:30 AM - Globe NewsWire
Form 8-K Cadrenal Therapeutics, For: Apr 30
April 30, 2026 8:45 AM - SEC Filing
Cadrenal receives FDA guidance for phase 3 trial of HIT treatment
April 30, 2026 8:30 AM - StreetInsider
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
April 30, 2026 8:30 AM - Globe NewsWire
Form EFFECT Cadrenal Therapeutics,
April 30, 2026 6:16 AM - SEC Filing
Form 424B3 Cadrenal Therapeutics,
April 29, 2026 5:30 PM - SEC Filing
Cadrenal Therapeutics (CVKD) files for 1.18M share offering by selling stockholders
April 21, 2026 6:09 AM - StreetInsider
Form S-3 Cadrenal Therapeutics,
April 21, 2026 6:03 AM - SEC Filing
Cadrenal Therapeutics (CVKD) PT Lowered to $13 at H.C. Wainwright
April 7, 2026 11:34 AM - StreetInsider
Form D Cadrenal Therapeutics,
April 6, 2026 4:06 PM - SEC Filing
Form 8-K Cadrenal Therapeutics, For: Mar 31
April 1, 2026 7:41 AM - SEC Filing
Form 424B5 Cadrenal Therapeutics,
April 1, 2026 7:30 AM - SEC Filing
Form 10-K Cadrenal Therapeutics, For: Dec 31
March 31, 2026 9:04 AM - SEC Filing
Form 8-K Cadrenal Therapeutics, For: Mar 31
March 31, 2026 8:55 AM - SEC Filing
Cadrenal Therapeutics reports Q4 2025 results, FDA meeting progress
March 31, 2026 8:45 AM - StreetInsider
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
March 31, 2026 8:45 AM - Globe NewsWire
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
March 13, 2026 8:35 AM - StreetInsider
Form 8-K Cadrenal Therapeutics, For: Mar 12
March 12, 2026 8:06 AM - SEC Filing
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
March 12, 2026 8:01 AM - Globe NewsWire
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
March 10, 2026 10:22 AM - StreetInsider
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
March 10, 2026 10:21 AM - Globe NewsWire
Full Article List
